Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve (NASDAQ:ZBIO)

Summary by Seeking Alpha
Zenas BioPharma is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date. Read why ZBIO stock is a Buy.

2 Articles

Seeking AlphaSeeking Alpha
Reposted by
The Business TimesThe Business Times
Lean Right

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve (NASDAQ:ZBIO)

Zenas BioPharma is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date. Read why ZBIO stock is a Buy.

·Ra'anana, Israel
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in Ra'anana, Israel on Monday, October 5, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Waltham, Massachusetts icon

Waltham, Massachusetts

United Kingdom icon

United Kingdom

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal